Shots:

• The companies collaborates on multiple projects- being the first for inflammatory bowel disease(IBD) to develop and discover therapies for treating Immune-Mediated Inflammatory Diseases (IMIDs)
• The focus of the collaboration will allow Gossamer’s immunology research and development team to utilize IMIDomics’ unique clinical and molecular patient database for product discovery and development strategy
• IMIDomics’ platform has access to dynamic and high-quality IMID patient biobank- clinical data- proprietary multiomics molecular data and world-class clinical expertise

Click here to read full press release/ article | Ref: BioSpace | Image: Behance